2005
DOI: 10.1007/s00280-004-0963-2
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Our findings suggest that the combination of MMC and capecitabine in patients with advanced colorectal cancer pretreated with combination regimens including 5-FU, FA and CPT-11 or 5-FU, FA and L-OHP is safe. However, this regimen had a poor response rate and no definitive contribution to increasing patients' overall survival time. Further evaluation of other salvage regimens seems to be warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
20
0

Year Published

2007
2007
2011
2011

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 41 publications
references
References 21 publications
0
20
0
Order By: Relevance
“…Only very few studies on ''fourth line therapy'' in mCRC patients pre-treated with FU/FA, irinotecan and oxaliplatin have been published [18,19]. Rosati et al treated 21 patients with raltitrexed and mitomycin-C but no patient had tumour regression and median survival was only 5 months [18].…”
Section: Discussionmentioning
confidence: 99%
“…Only very few studies on ''fourth line therapy'' in mCRC patients pre-treated with FU/FA, irinotecan and oxaliplatin have been published [18,19]. Rosati et al treated 21 patients with raltitrexed and mitomycin-C but no patient had tumour regression and median survival was only 5 months [18].…”
Section: Discussionmentioning
confidence: 99%
“…A recent review pointed out that OS was significantly correlated with the percentage of patients who received all three drugs . In a recent update, they demonstrated that a strategy of making all three active agents available was more important than the use of doublet upfront (Grothey and Sargent, 2005 (Rosati et al, 2003;Lim et al, 2005). Rosati et al (2003) treated 21 patients with raltitrexed and mitomycin-C but no patient had tumor regression, and median survival was only 5 months.…”
Section: Second-line Therapymentioning
confidence: 99%
“…Rosati et al (2003) treated 21 patients with raltitrexed and mitomycin-C but no patient had tumor regression, and median survival was only 5 months. Lim et al (2005) also treated 21 patients but with a combination of capecitabine and mitomycin-C. Only one patient had tumor regression, TTP was 2.6 months and OS was 6.5 months and they concluded that the regimen did not add to increasing patients OS.…”
Section: Second-line Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…Four patients (40%) had a poorly differentiated adenocarcinoma, compared to 10.7% in the study by Jeung et al Therefore, these differences may have an impact on the tumor response in this study. Additionally, in a phase II trial of a combination of MMC and another oral fluoropyrimidine, capecitabine, as third-line chemotherapy in patients with advanced CRC, only one out of 19 patients (4.8%) showed a partial response (13). These results suggest that the combination of MMC and an oral fluoropyrimidine, such as capecitabine or S-1, has poor activity in advanced CRC patients pretreated with irinotecan and oxaliplatin sequentially in combination with infused 5-FU/LV.…”
Section: Discussionmentioning
confidence: 99%